BridgeBio's Chief Regulatory Affairs Officer Adora Ndu on PDUFA VII Reauthorization

<p>On the heels of Congress&apos; reauthorization of the Prescription Drug User Fee Authorization (PDUFA) Act, BridgeBio&apos;s Chief Regulatory Affairs Officer, Adora Ndu, explains the Commitment Letter, the programs that may be rolled out under PDUFA VII, why right-sizing CBER will help the cell and gene sector going forward as well as how sponsor companies can prepare for 2023 from a regulatory perspective.</p>